Recent news on Fludarabine

Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment ...  -  May 17, 2007
PharmaLive.com (press release),The PIX303 trial will examine the time to disease progression for the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the

Pixantrone Granted Fast Track Designation By FDA For Relapsed ...  -  May 8, 2007
Medical News Today (press release),The FDA also noted that the proposed phase III trial in combination with fludarabine and rituximab "has the potential to demonstrate an effect on a serious

Pixantrone Granted Fast Track Status for Treating Relapsed ...  -  May 8, 2007
Facts and Comparisons,Pixantrone in combination with fludarabine and rituximab is being investigated to determine its effects on the time to disease progression in patients with

Genta Incorporated Announces First Quarter 2007 Financial Results ...  -  May 8, 2007
PR Newswire (press release),...with relapsed or refractory CLL were randomly assigned to receive fludarabine plus cyclophosphamide (Flu/Cy) chemotherapy with or without Genasense.

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  26 Apr 2007
WebWire (press release),...is currently indicated for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy.

Santaris Pharma presents positive preclinical data on SPC2996 at ...  -  Apr 18, 2007
PipelineReview.com (press release),The model appears to be validated by the efficacy of the fludarabine in clearing engrafted human CLL cells. The demonstration that single agent therapy with

Cell Therapeutics, Inc. (CTI) Files for Special Protocol ...  -  Apr 4, 2007
Drug Newswire (press release),The trial, PIX303, will examine the complete remission rates and time to disease progression of the combination regimen of fludarabine, pixantrone and

Genta Appeals FDA Decision on Genasense(R) in CLL  -  Apr 5, 2007
Drug Newswire (press release),In the pivotal Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive fludarabine plus cyclophosphamide (Flu/Cy)

Genzyme, Bayer File for New FDA Drug OK  -  Apr 4, 2007
Forbes,Currently, the drug is approved to treat the disease in patients that have been treated with an alkylating agent and have failed fludarabine therapy.

Bayer submits supplementary license application for leukemia drug ...  -  Apr 4, 2007
Forbes,...approved to treat B-CLL patients who have previously been treated with an alkylating agent and who have failed chemotherapy treatment using Fludarabine.

Genzyme, Bayer file to expand Campath product label  -  Apr 4, 2007
MarketWatch...for the treatment of B-cell chronic lymphocytic leukemia patients who have been treated with an alkylating agent and have failed fludarabine therapy.

Genzyme seeks Campath expanded use  -  Apr 4, 2007
United Press International...approved as a second line therapy, or for B-CLL patients who were previously treated with an alkylating agent and have failed fludarabine therapy.

Genzyme Files for Expanded Label for Campath® as First-Line Treatment  -  Apr 7, 2007
WebWire (press release),Campath is currently approved for the treatment of B-CLL patients who have been previously treated with an alkylating agent and have failed fludarabine

Genta Appeals FDA Decision on Genasense(R) in CLL  -  Apr 4, 2007
PR Newswire (press release),Genasense in CLL In the pivotal Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive fludarabine plus cyclophosphamide

Expanded Label Filed for Campath®  -  Apr 9, 2007
Cancer Consultants (press release),...treatment of patients with B-CLL who have received prior therapy with an alkylating agent and have failed prior treatment with Fludara® (fludarabine).

Genzyme seeks expanded FDA approval for Campath  -  Apr 5, 2007
Bizjournals.com,...to treat patients with B-cell chronic lymphocyctic leukemia who have been treated with alkylating agents but who have failed fludarabine therapy.

CVS/Caremark CEO got $24m pay package in '06  -  Apr 4, 2007
Boston Globe,Currently, the drug is approved to treat the disease in patients that have been treated with an alkylating agent and have failed fludarabine therapy. (AP)

Genta Appeals FDA Decision On Genasense In CLL - Update  -  Apr 4, 2007
Trading Markets,The company conducted a pivotal Phase 3 trial, involving patients with relapsed or refractory CLL, who were randomly assigned to receive fludarabine plus

Pharma Sector: Few Newsmakers Of The Week - Pfizer, Merck, Glaxo ...  -  Apr 6, 2007
Trading Markets,...(B-CLL | charts | news | PowerRating) in patients who have been previously treated with an alkylating agent and have failed fludarabine therapy.

First Antisense Drug Provides Benefit To Subset Of Chronic ...  -  Feb 20, 2007
Medical News Today (press release),Fludarabine is a newer chemotherapy drug that is now being used as first treatment for many patients, according to O'Brien. Oblimersen is an experimental

Genta Announces the Company Will Appeal FDA Action on New Drug ...  -  Feb 12, 2007
Drug Newswire (press release),In the pivotal Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive fludarabine plus cyclophosphamide (Flu/Cy)

Genta publishes encouraging results on cancer therapy  -  Feb 14, 2007
Pharmaceutical Business ReviewIn the trial patients with relapsed or refractory chronic lymphocytic leukemia (CLL) received fludarabine plus cyclophosphamide chemotherapy with or without

Genta Announces the Company Will Appeal FDA Action on New Drug ...  -  Feb 6, 2007
PR Newswire (press release),Genasense in CLL In the pivotal Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive fludarabine plus cyclophosphamide

Lumiliximab Granted Orphan Drug Status and Fast Track Status  -  Feb 9, 2007
Cancer Consultants (press release),Biogen Idec has initiated a clinical trial comparing lumiliximab in combination with FCR (fludarabine, cyclophosphamide and rituximab) to FCR alone in

Genasense® Combination Therapy Effective for CLL  -  Feb 20, 2007
Cancer Consultants (press release),Researchers involved in a multicenter trial have reported that the addition of Genasense (oblimersen, Bcl-2 antisense) to Fludara® (fludarabine) and

Addition of Genasense® to Chemotherapy Improves Responses in CLL  -  Feb 16, 2007
Cancer Consultants (press release),Randomized Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory

Celgene Q4 2006 Earnings Call Transcript  -  Feb 1, 2007
Seeking Alpha,Also, we are investigating REVLIMID in various combinations such as Rituxan or Fludarabine in both untreated and relapse refectory CLL patients.

Pro-Pharmaceuticals Collaborates with Chemwerth to Scale-up ...  -  Feb 20, 2007
PharmaLive.com (press release),Etoposide USP, Fludarabine Phosphate, Gemcitabine HCl USP, Ifosfamide USP, Irinotecan HCl 3H2O, Mitoxantrone HCl USP/PhEur and Thiotepa USP.

New Lymphocytic Leukemia Treatment Found  -  Feb 16, 2007
KLTV,The drug in the study, oblimersen (Genasense), provided benefit for a specific subset of patients -- those who are still sensitive to fludarabine,

Biogen Idec Reports Full Year and Fourth Quarter 2006 Results  -  Feb 15, 2007
WebWire (press release),...may be synergistic with fludarabine, cyclophosphamide and rituximab (FCR), an emerging standard of care for chronic lymphocytic leukemia (CLL) patients.

Genmab Announces Year End 2006 Financial Results  -  Feb 13, 2007
PR Newswire (press release),HuMax-CD20 in combination with fludarabine and cyclophosphamide for CLL Advanced pre-clinical pipeline - HuMax-CD38(TM) shown to be first antibody known

Genzyme Reports Financial Results for Fourth Quarter of 2006 and ...  -  Feb 14, 2007
WebWire (press release),Campath is currently indicated for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy.

The Future Of Allogeneic Hematopoietic Stem Cell Transplantation ...  -  Feb 5, 2007
Medical News Today (press release),In that report, patients received a conditioning regimen of fludarabine/cyclophosphamide, prior to BMT. The incidence of acute graft versus host disease

5AM Solutions Adds Dr. Dan Von Hoff to Advisory Board  -  Jan 31, 2007
Emediawire (press release),He and his colleagues were involved in the early development of drugs that are now routinely used to treat cancer, including: mitoxantrone, fludarabine,

'Impressive' Complete Remission And 'Survival Data In Relapsed ...  -  Dec 25, 2006
Medical News Today (press release),In a poster session, Dr. Fayad presented results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for treatment

Nektar Appoints Howard W. Robin President and CEO  -  Jan 8, 2007
PharmaLive.com (press release),...multiple sclerosis and Fludara(R) (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million.

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),Campath is currently indicated for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy.

Phase I/II Data Support Continued Development Of Biogen Idec's ...  -  Jan 2, 2007
Medical News Today (press release),...may be synergistic with fludarabine, cyclophosphamide and rituximab (FCR), an emerging standard of care for chronic lymphocytic leukemia (CLL) patients.

Genmab Initiates HuMax-CD20 Front Line CLL Study  -  Dec 24, 2006
Medical News Today (press release),Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of HuMax-CD20(TM) (ofatumumab) in combination with fludarabine and cyclophosphamide

'Impressive' Complete Remission And 'Survival Data In Relapsed ...  -  Dec 25, 2006
Medical News Today (press release),Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent NHL. ...

'Impressive' Complete Remission and 'Durable' Survival Data in ...  -  Dec 10, 2006
PR Newswire (press release),..."Given the results observed in this study, more studies with this regimen are warranted." Pixantrone in Combination with Fludarabine, Dexamethasone and ...

'Impressive' Complete Remission and 'Durable' Survival Data in ...  -  Dec 10, 2006
Yahoo! News (press release)In a poster session, Dr. Fayad presented results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for treatment of ...

Genmab Initiates HuMax-CD20 Front Line CLL Study  -  Dec 24, 2006
Medical News Today (press release),Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of HuMax-CD20(TM) (ofatumumab) in combination with fludarabine and cyclophosphamide (FC ...

Genasense Not Approvable' In CLL; Europe's Ruling Next  -  Dec 15, 2006
BioWorld Online,York, had expected an approvable letter, with the FDA insisting on another Phase III trial evaluating CLL patients who have relapsed from fludarabine therapy. ...

Randomized Trial of Genasense(R) in Advanced CLL Shows that ...  -  Dec 11, 2006
PR Newswire (press release),In this trial, 241 patients were randomly assigned to receive fludarabine and cyclophosphamide (Flu/Cy) with or without Genasense. ...

Genasense Trial in Chronic Lymphocytic Leukemia Shows Significant ...  -  Dec 11, 2006
PharmaLive.com (press release),In this multinational randomized trial, 241 relapsed or refractory CLL patients were randomly assigned to receive fludarabine and cyclophosphamide (Flu/Cy ...

Fludara®-Novantrone® Induction and Zevalin® Consolidation ...  -  Dec 19, 2006
Cancer Consultants (press release),Researchers from Italy have reported a 100% complete response (CR) rate to induction therapy with oral Fludara (fludarabine) and Novantrone (mitoxantrone) (FM ...

Genmab Initiates Humax-CD20 Front Line CLL Study  -  Dec 12, 2006
PipelineReview.com (press release),Announced today it has initiated a Phase II study of HuMax-CD20™ (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) to treat chronic ...

Transplant drug fights leukemia  -  Dec 11, 2006
Monsters and Critics.com,He said most initial treatments for the disease include fludarabine-containing regimens, although many doctors are experimenting with use of drugs such as ...

New drugs attack blood diseases  -  Dec 12, 2006
Monsters and Critics.com,Lumiliximab was added to a standard treatment regimen of anti-cancer drugs fludarabine, cyclophosphamide and rituximab in the early clinical trial. ...

Biogen Idec says positive data from Phase I/II study of ...  -  Dec 11, 2006
Forbes,Data indicated it may be synergistic with fludarabine, cyclophosphamide and rituximab, an emerging standard of care for chronic lymphocytic leukemia patients. ...

Campath shown to be more effective in treating leukemia than ...  -  Dec 11, 2006
San Antonio Business Journal,...approved Campath in 2001 for the treatment of B-CLL in patients who have already been treated with alkylating agents and have failed fludarabine therapy. ...

Alemtuzumab Appears Promising as First-Line B-cell Chronic ...  -  Dec 11, 2006
DG News...for the treatment of B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy. ...

ASH: Mylotarg Boosts AML Disease-Free Survival  -  Dec 12, 2006
MedPage Today,...to conventional chemotherapy with either danorubicin plus Ara-C (cytarabine), the same two drugs plus etoposide, or FLAG-IDA, a combination fludarabine, Ara-C ...

Lenalidomide Helpful in Refractory Chronic Lymphocytic Leukemia  -  Dec 15, 2006
Cancerpage.com,...disease. All had at least one prior treatment but had relapsed or been refractory to treatment; 51% were refractory to fludarabine. ...

Gemtuzumab Induction Therapy Improved Progression Free Survival ...  -  Dec 14, 2006
DG News...to 1 of 3 standard chemotherapy regimens: 1. daunorubicin and cytarabine; 2. cytarabine, daunorubicin and etoposide; 3. fludarabine, cytarabine, idarubicin and ...

Genmab pares down list of potential new partners  -  Dec 11, 2006
Pharma Times (subscription),...were also published last week. Genmab has also just announced the start of a Phase II study of HuMax-CD20 in combination with fludarabine and. ...

131 Abstracts Evaluating Celgene Products to Be Presented at the ...  -  Dec 7, 2006
Yahoo! News (press release)Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment; Abstract ...

Genta Clinical Programs Featured In Presentations At Annual ...  -  Dec 5, 2006
Medical News Today (press release),...lymphocytic leukemia (CLL) is strongly affected by the use of CT Scanning: Results from a prospective randomized trial of fludarabine plus cyclophosphamide (Flu ...

Data From Phase III Comparative Study Show Campath(R) Superior To ...  -  Dec 12, 2006
Medical News Today (press release),Campath is currently indicated for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. ...

Phase I/II Data Support Continued Development of Biogen Idec's ...  -  Dec 11, 2006
PharmaLive.com (press release),...a Phase I/II study of an investigational anti-CD23 monoclonal antibody, lumiliximab, suggesting it may be synergistic with fludarabine, cyclophosphamide and ...

Genta Provides Update on Analysis of Phase 3 Trial of Genasense(R) ...  -  Dec 8, 2006
Yahoo! News (press release)The Company has submitted a New Drug Application (NDA) to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for ...

Rituxan® and Campath® Show Significant Activity in Newly ...  -  Dec 8, 2006
Cancer Consultants (press release),Campath has significant activity for the treatment of patients with CLL who have failed Fludara® (fludarabine) and more recently has been evaluated as initial ...

Genta drug works in non-refractory CLL  09 Nov 2006
The study involved 241 patients with relapsed or refractory CLL who were randomly assigned to receive fludarabine plus cyclophosphamide chemotherapy with or ... -United Press International Celgene Q3 2006 Earnings Call Transcript  Oct 26, 2006
...versus placebo, to determine whether this treatment can delays progression of CLL in patients who have complete its standard Fludarabine based treatment for ... -Seeking Alpha, Pharma Sector - Few Newsmakers Of The Week: Tercica, Adherex ...  Nov 4, 2006
...chronic lymphocytic leukemia or CLL were enrolled of which 50% of the patients received two chemotherapy drugs namely fludarabine and cyclophosphamide in ... -Trading Markets, FDA Extends Review Period For Genasense(R) New Drug Application In ...  Oct 31, 2006
...multicenter, multinational trial in which 241 patients with relapsed or refractory CLL received standard chemotherapy (fludarabine plus cyclophosphamide) with ... -Medical News Today (press release), Genta Receives Special Protocol Assessment from FDA for Randomized ...  Oct 9, 2006
...which will be conducted in symptomatic patients who have not previously received chemotherapy, would randomize patients to receive fludarabine plus rituximab ... -Drug Newswire (press release), Nipent®, Cytoxan® and Rituxan® Effective for Untreated Poor ...  Oct 30, 2006
One of the most active drug combinations for the treatment of CLL and low-grade NHL is Fludara® (fludarabine), Cytoxan and Rituxan. ... -Cancer Consultants (press release), Medical apartheid as English cancer patients are denied life ...  Oct 20, 2006
...been turned down by NICE because they do not buy enough time for patients - along with four drugs which can slow the onset of dementia and Fludarabine, a drug ... -Daily Mail - UK, Genentech Q3 2006 Earnings Call Transcript  Oct 10, 2006
This global study is being led by Roche and compares fludarabine cyclophosphamide and chemotherapy to this chemotherapy combined with Rituxan. ... -Seeking Alpha, Genmab Hosts Research, Development and Business Update  Oct 18, 2006
Lymphocytic Leukemia indication is also expected to move to front line studies with a Phase II trial combining HuMax-CD20 with fludarabine and cyclophosphamide ... -Earthtimes.org Genmab Hosts Research, Development and Business Update  Oct 18, 2006
The. fludarabine and cyclophosphamide planned before the end of this year. 2007, pending results of the ongoing Phase II program. Operating Officer at Genmab. ... -PharmaLive.com (press release), Awaiting Genasense Decision, Genta Gets $16M In Stock Sale  Sep 20, 2006
Genta filed a new drug application in December to use Genasense (oblimersen sodium) injection with fludarabine and cyclophosphamide in patients with relapsed ... -BioWorld Online

Cancer drugs usage 'sees boost'  Sep 20, 2006
...increase of 55%. Other did not fare so well. Chemotherapy drug fludarabine prescriptions rose by just 11%. The survey also found ... -BBC News

Multiple sclerosis: Campath more effective than Rebif  Sep 17, 2006
...the treatment of B-cell chronic lymphocytic leukemia ( B-CLL ) in patients who have been treated with alkylating agents and who have failed Fludarabine therapy ... -Xagena.it

Genta's Stock Slides Again As ODAC Turns Back Genasense  Sep 6, 2006
In the randomized trial in question, Genasense was added to fludarabine and cyclophosphamide (GFC) in about half of the study's 241 patients, while the ... -BioWorld Online

Independent Analysis of EORTC Trial Confirms Survival Impact of ...  Sep 19, 2006
The Company has submitted a New Drug Application (NDA) to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for ... -PR Newswire

New Strain Of Mice Mimics Chronic Leukemia And Will Aid Drug ...  Aug 25, 2006
...to 12 years. The standard treatment for CLL is the drug fludarabine, but the disease often becomes resistant to the drug. This TCL ... -Medical News Today

Pharmion Corporation Initiates Phase II Clinical Trial With ...  Sep 15, 2006
...symptomatic. Standard therapy includes IV treatment with rituximab with or without an agent such as fludarabine or 2-chlorodeoxyadenosine. ... -Yahoo! News

Genzyme Reports Interim Results from Trial of Campath(R) for ...  Sep 14, 2006
...the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. ... -PR Newswire

Genta Says FDA Has Published Briefing Documents For ODAC Review Of ...  Sep 5, 2006
...a New Drug Application (NDA | charts | news | PowerRating) to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide ... -Trading Markets

ASH: Mylotarg Boosts AML Disease-Free Survival  -  12 Dec 2006
MedPage Today,...the same two drugs plus etoposide, or FLAG-IDA, a combination fludarabine, Ara-C, granulocyte colony stimulating factor and idarubicin.

Campath shown to be more effective in treating leukemia than ...  -  12 Dec 2006
Phoenix Business Journal,Campath in 2001 for the treatment of B-CLL in patients who have already been treated with alkylating agents and have failed fludarabine therapy.

'Impressive' Complete Remission and 'Durable' Survival Data in ...  -  Dec 11, 2006
Drug Newswire (press release),In a poster session, Dr. Fayad presented results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for treatment

Genmab pares down list of potential new partners  -  Dec 11, 2006
Pharma Times (subscription),Genmab has also just announced the start of a Phase II study of HuMax-CD20 in combination with fludarabine and. Ms Drakeman refused to be drawn on which

Genasense(R) Trial in Chronic Lymphocytic Leukemia Shows ...  -  Dec 11, 2006
Drug Newswire (press release),In this multinational randomized trial, 241 relapsed or refractory CLL patients were randomly assigned to receive fludarabine and cyclophosphamide (Flu/Cy)

Genta Clinical Programs Featured In Presentations At Annual ...  -  Dec 5, 2006
Medical News Today (press release),The Company has submitted a New Drug Application (NDA) to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide

Rituxan® and Campath® Show Significant Activity in Newly Diagnosed ...  -  Dec 8, 2006
Cancer Consultants (press release),Campath has significant activity for the treatment of patients with CLL who have failed Fludara® (fludarabine) and more recently has been evaluated as

Genta Clinical Programs Featured in Presentations at Annual ...  -  Dec 4, 2006
Earthtimes.org...randomized trial of fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense (oblimersen) in patients with relapsed or refractory disease.

Campath® Safe and Active in Patients With CLL After Extensive ...  -  Nov 15, 2006
Cancer Consultants (press release),Campath is currently approved for treatment of patients with B-cell CLL whose disease has stopped responding to alkylating agents and Fludara® (fludarabine)

Campath® Safe and Active in Patients with CLL After Extensive ...  -  Nov 13, 2006
Cancer Consultants (press release),...three prior treatment strategies, and 59% of patients had stopped responding to the commonly used chemotherapy agent Fludara® (fludarabine).

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional